Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Top Cited Papers
- 7 March 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (6) , 1142-1165
Abstract
Disease Overview: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%–20% over 3–5 years).Diagnosis: Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109/L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, 95% harbor somatic mutations: TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), RAS pathway (~30%), and others. The presence of ASXL1 and DNMT3A mutations and absence of TET2 mutations negatively impact overall survival (ASXL1WT/TET2MT genotype being favorable).Risk Stratification: Several risk models serve similar purposes in identifying high‐risk patients that are considered for allogeneic stem cell transplant (ASCT) earlier than later. Risk factors in the Mayo Molecular Model (MMM) include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 109/L, hemoglobin 9/L, and the presence of circulating immature myeloid cells; the resulting 4‐tiered risk categorization includes high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor), and low (no risk factors); the corresponding median survivals were 16, 31, 59, and 97 months. CMML is also classified as being “myeloproliferative (MP‐CMML)” or “myelodysplastic (MD‐CMML),” based on the presence or absence of leukocyte count of ≥13 × 109/L.Treatment: ASCT is the only treatment modality that secures cure or long‐term survival and is appropriate for MMM high/intermediate‐2 risk disease. Drug therapy is currently not disease‐modifying and includes hydroxyurea and hypomethylating agents; a recent phase‐3 study (DACOTA) comparing hydroxyurea and decitabine, in high‐risk MP‐CMML, showed similar overall survival at 23.1 versus 18.4 months, respectively, despite response rates being higher for decitabine (56% vs. 31%).Unique Disease Associations: These include systemic inflammatory autoimmune diseases, leukemia cutis and lysozyme‐induced nephropathy; the latter requires close monitoring of renal function during leukocytosis and is a potential indication for cytoreductive therapy.Keywords
Funding Information
- Center for Biomedical Informatics and Information Technology (R01CA272496)
This publication has 157 references indexed in Scilit:
- Monocytosis in polycythemia vera: Clinical and molecular correlatesAmerican Journal of Hematology, 2017
- DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemiaAmerican Journal of Hematology, 2016
- Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosisAmerican Journal of Hematology, 2015
- Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1‐PDGFRA mutationAmerican Journal of Hematology, 2015
- Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcomeAmerican Journal of Hematology, 2015
- Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic‐French Consortium StudyAmerican Journal of Hematology, 2014
- Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institutionAmerican Journal of Hematology, 2014
- What is a promonocyte?American Journal of Hematology, 2013
- Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevanceAmerican Journal of Hematology, 2012
- FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaAmerican Journal of Hematology, 2012